Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Metagenomi, Inc. Common Stock (MGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MGX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.5
1 Year Target Price $9.5
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.12% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.31M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Price to earnings Ratio - | 1Y Target Price 9.5 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 1.23 - 4.92 | Updated Date 09/16/2025 |
52 Weeks Range 1.23 - 4.92 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -257.99% | Operating Margin (TTM) -246.53% |
Management Effectiveness
Return on Assets (TTM) -17.44% | Return on Equity (TTM) -37.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -92191368 | Price to Sales(TTM) 2.02 |
Enterprise Value -92191368 | Price to Sales(TTM) 2.02 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 37533100 | Shares Floating 25276690 |
Shares Outstanding 37533100 | Shares Floating 25276690 | ||
Percent Insiders 28.09 | Percent Institutions 19.3 |
Upturn AI SWOT
Metagenomi, Inc. Common Stock
Company Overview
History and Background
Metagenomi, Inc. is a gene editing company focused on discovering and developing novel CRISPR-based technologies. Founded in 2018, it leverages metagenomics to identify and engineer new gene editing systems with improved efficacy and safety profiles. The company went public in February 2024.
Core Business Areas
- Therapeutic Development: Developing gene editing therapies for a range of genetic diseases, including liver, lung, and central nervous system disorders.
- Platform Discovery: Identifying and characterizing novel CRISPR-based gene editing systems from diverse environmental sources through metagenomics.
- Technology Licensing: Licensing its gene editing technology platform to other companies for therapeutic and research applications.
Leadership and Structure
Brian C. Thomas is the co-founder and CEO. The company has a board of directors with expertise in biotechnology, finance, and drug development. The organizational structure is typical of a biotech company, with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- MGON-DTLA: A lead preclinical program targeting a specific rare genetic disorder. Data is currently unavailable about market share or revenue at this time. Key competitors are companies developing similar gene editing therapies, such as Editas Medicine, Beam Therapeutics, and Intellia Therapeutics.
- CRISPR Discovery Platform: A proprietary metagenomics-based platform for identifying novel CRISPR systems. Revenue is generated through licensing agreements and partnerships. The platform competes with other gene editing technology platforms, like those offered by Caribou Biosciences and Mammoth Biosciences.
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, driven by advances in CRISPR technology and increasing demand for therapies for genetic diseases. The market is highly competitive, with many companies developing gene editing tools and therapies.
Positioning
Metagenomi is positioned as a leader in the discovery of novel CRISPR systems. Its metagenomics approach provides a unique advantage in identifying diverse and potentially more effective gene editing tools.
Total Addressable Market (TAM)
The gene editing market is expected to reach hundreds of billions of dollars in the coming years. Metagenomi is positioned to capture a significant share of this market with its innovative technology platform.
Upturn SWOT Analysis
Strengths
- Novel CRISPR discovery platform
- Strong intellectual property portfolio
- Experienced management team
- Potential for partnerships and licensing agreements
Weaknesses
- Early-stage company with limited clinical data
- High research and development costs
- Dependence on key partnerships
- Risk of competition from larger companies
Opportunities
- Expanding into new therapeutic areas
- Developing partnerships with pharmaceutical companies
- Securing regulatory approvals for gene editing therapies
- Capitalizing on the growing demand for gene editing technologies
Threats
- Competition from established gene editing companies
- Regulatory hurdles and uncertainties
- Potential safety concerns with gene editing therapies
- Ethical concerns surrounding gene editing
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BEAM
Competitive Landscape
Metagenomi competes with established gene editing companies like CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics. Its advantage lies in its novel CRISPR discovery platform. However, it faces the challenges of being a smaller company with limited clinical data.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth data is available due to the company's early stage. The IPO represented a major milestone in the company's growth.
Future Projections: Future growth is dependent on the successful development and commercialization of its gene editing therapies. Analyst estimates vary but generally project significant revenue growth in the coming years.
Recent Initiatives: Recent initiatives include advancing preclinical programs, expanding the CRISPR discovery platform, and establishing partnerships with pharmaceutical companies.
Summary
Metagenomi is an early-stage gene editing company with a unique technology platform. Its novel CRISPR discovery approach provides a competitive advantage. However, it faces risks associated with drug development and competition from larger companies. The company needs to successfully advance its clinical programs and secure partnerships to achieve its growth potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Metagenomi, Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Company Press Releases
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Metagenomi, Inc. Common Stock
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2024-02-09 | Co-Founder, CEO & Chairman of the Board Dr. Brian Charles Thomas Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 171 | Website https://metagenomi.co |
Full time employees 171 | Website https://metagenomi.co | ||
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.